Zealand Pharma A/S

Good afternoon, everyone, and welcome to Zealand Pharma's third quarter 2021 financial results conference call. Today's call is being recorded. At this time, I would like to turn the call over to Matt Dallas, Senior Vice President and Chief Financial Officer. Matt, please go ahead.

Thank you, operator. Welcome and thank you for joining us today to discuss Zealand's third quarter results for 2021. I'm Matt Dallas, Senior Vice President and Chief Financial Officer at Zeeland. With me today are Zeeland's President and Chief Executive Officer, Emmanuel Duac, President of Zeeland Pharma U.S., Frank Sanders, and Chief Medical Officer and Head of Development, Adam Steensburg. You can find the related company announcement and additional supporting information on our website at zeelandpharma.com. I would like to point out that we will be making four looking statements that are subject to risks and uncertainties. These statements are valid only as of today, and the company assumes no obligation to update them except as required by law. Please refer to recent filings for a more complete picture of risk and other factors. And with that, I will turn the call over to President and CEO, Emmanuel Doula.

Thank you, Matt. And thanks to everyone for joining today. The third quarter of dates we will discuss on today's call underscore Zealand's evolution as a fully integrated biopharmaceutical company. In Q3, We continue to execute on our commercial goals following the launch of Zegalog in the US, while also sustaining momentum across the rest of our pipeline by advancing multiple clinical and preclinical programs that leverage our innovative peptide platform to address unmet needs in type 1 diabetes and rare disease. This continuous progress positions us well to achieve our goal of offering five marketed products by 2025 to patients around the globe with high-end medical needs. Slide four illustrates the development of our company in relation to the successful execution of our strategy. Later in the call, our CMO and head of research and development, Adam Stinsberg, will discuss these pipelines updates in greater detail, including updates on glipagritide in the treatment of Scholl-Powell syndrome, or SBS, information on pre-heal data from our analog and clinical data from our glucagon GLP-1 dual agonist partnered with BI that were presented at the recent Obesity Society annual meeting. And more details on our collaboration agreement with Deca Research and Development Corporation to advance development of an infusion pump to be used with Tazic-Glucagon, currently under investigation as a potential treatment option for congenital hyperinsulinism. But first, Frank Sanders, President of Xenopharma US, will discuss the work our commercial team has been doing on the Zegalog launch.